The impact of workload changes and staff availability on IV chemotherapy services

Journal of Oncology Pharmacy Practice

Volumn 9, Issue 4, 2003, Pages 123-128

  Summerhayes, Maxwell ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Chemotherapy; Nurses; Pharmacists; Reconstitution; Workload

Indexed keywords

CYTOTOXIC AGENT; FLUOROPYRIMIDINE;

ARTICLE; ASEPSIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HEALTH SURVEY; HUMAN; METASTASIS; NURSING STAFF; PHARMACIST; POSTAL MAIL; PRIORITY JOURNAL; QUESTIONNAIRE; STRESS; UNITED KINGDOM; WORKLOAD;

EID: 0344465948     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155203jp112oa     Document Type: Article

References (13)

1. Anon. Too few trainees in hospital pharmacy. Pharm J 2002;268: 599.
2. British Oncology Pharmacy Association. The NHS cancer plan and the pharmacy contribution to cancer care. London: BOPA, 2001. Retrieved 12 September 2003 from (www.bopa.cix.co.uk/Publications/OncologyPharmacy.pdf)
3. Summerhayes M. Choice of chemotherapy regimen for advanced colorectal cancer. Clin Oncol (R College Radiol) 2003; 14: 520-21.
4. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75.
5. Twelves C, on behalf of the Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 2002; 38: S15-S20.
6. Pazdur R, Douillard J-Y, Skillings JR et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer (Abstract). Proc Am Soc Clin Oncol 1996; 18: 18-29.
7. Twelves C, Cassidy J. Which endpoints should we use in evaluating the use of novel flouropyrimidine regimens in colorectal cancer? Br J Cancer 2002; 86: 1670-76.
8. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-15.
9. Borner M, Schöffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous flourouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-58.
10. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K. Capecitabine (Xeloda™) improves medical resource use compared with 5-flourouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604.
11. Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham National Health Science Trust. J Oncol Pharm Pract 1998; 4: 10-14.
12. Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health System Pharm 2001; 58: 1760-64.
13. Ratain MJ. Body-surface area as a basis for dosing of anticancer agents. J Clin Oncol 1998; 16: 2297-98.